1.Date of occurrence of the event:2022/08/09
2.Company name:Maxigen Biotech Inc
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:N/A
6.Countermeasures:N/A
7.Any other matters that need to be specified:
Maxigen Biotech Inc. (TWSE: 1783) today announced its net revenues
for July 2022.
On a consolidated basis, revenues for July 2022 were
approximately NT$ 46.993 million, an increase of 33.47 percent
over the same period in 2021.
Revenues for January through July 2022 totaled
NT$ 324.509 million, an increase of 21.41 percent compared to
the NT$ 267.291 million for the same period in 2021.
